AllergiQTTM – Quick Test Targets; FDA-cleared and easily administered skin test for environmental and food allergens USA Equities’ Allergy Program, which includes screening, testing, and immunotherapy treatment, is bolstered by non-allergy specialists working in primary care settings.
As the number of Allergists and Immunologists continues to decline, there is a compelling market opportunity with approximately 60 million Americans who suffer from Allergic Disorders.
Diagnostic allergy testing and preventative solutions provided by AllergiQTTM save physicians time and money for their practices.
On the 29th of November, 2021, in West Palm Beach, Florida By way of GLOBE NEWSWIRE: An allergy testing company, USA Equities Corp. (OTCQB: USAQ), has launched a new product, AllergiQTTM – Quick Test, which focuses on the allergy testing market and is aimed at independent primary care doctors in the United States.
Skin testing for environmental and food allergens can be done quickly and easily with the AllergiQTTM -Quick Test, which has been approved by the Food and Drug Administration. Twenty of the most common allergic and asthmatic allergens and symptoms are covered by this test, which is designed to be performed in a primary care provider’s office.
USA Equities Corp. Expands Market Presence with the Launch of Allergiqttm – Quick Test
Subcutaneous injections or sublingual immunotherapy drops can be prescribed by a doctor after a specific allergen has been identified, depending on the patient’s preference.
This latest new product introduction, AllergiQTTM, further expands our portfolio of income-generating products in the very attractive allergy test market,” USA Equities Corp. CEO Troy Grogan stated. Using QHSlab, our cloud-based software and technology platform for identifying patients who need an allergy test further enhances the product’s capabilities. USA Equities can therefore provide a complete solution to the market, including screening, testing, and immunotherapy treatment. Additionally, AllergiQTTM complements our existing AllergiEnd® product, allowing us to better serve smaller primary care practices. About 250,000 independent primary care physicians make up a significant portion of our total addressable market.
Given the size and growth rate of this market, we have a compelling opportunity to expand our product and service offerings in the field of allergic diseases. It is the sixth most common chronic disease in the United States and developed countries. The American College of Allergy, Asthma, and Immunology estimates that there are more than 50 million people in the United States and more than 400 million people worldwide who suffer from allergic disorders (ACAAI). As Grogan noted, “the number of allergists and immunologists is declining and is expected to continue decreasing,” despite the rising prevalence of allergies.
While saving time and maximizing the value of in-person visits, the AllergiQTTM product can generate additional revenue for physicians through physician reimbursement codes accepted by commercial payors, Medicare and Medicaid. An allergy sufferer’s point of view, allergies are associated with other chronic diseases such as asthma, COPD, hypertension, and coronary artery disease in addition to psychological disorders like stress and anxiety. At the earliest possible stage, physicians are able to identify allergies, which can lead to better treatment options, as well as preventative measures for other diseases, such as asthma and food allergies.
Aiming for non-allergy doctors in primary care settings.
The AllergiQTTM test is quick and painless, and it can be completed in the doctor’s office while you wait for your appointment. During a routine physical examination, a patient has two multiple head applicators without needles placed on their forearms.
In addition to environmental and food options, the twenty-allergen allergy skin test kit includes a variety of other potential triggers.
If the patient has any reactions, the doctor can quickly identify the allergen and provide a prescription remedy to begin treatment during the same office visit, there is no waiting for lab test results.
Prescription medicines formulated by the associated, accredited specialty pharmacy of AllergiQTTM allow physicians to implement evidence-based plans that treat allergies rather than their symptoms.
For primary care physicians, USA Equities Corp. provides digital medicine solutions and point-of-care-diagnostic tests. Doctors can use advanced artificial intelligence algorithms to quickly and effectively assess the response of their patients to healthcare screening. Using real-time data from patients to doctors, digital medicine can also monitor patients’ vital signs and evaluate the effects of newly prescribed medicines and treatments on their health. Diagnostic tests that are used in primary care are also sold and marketed by the company. With USA’s products and services, physicians can improve patient care while also boosting their practice’s service revenues.
Visit the company’s website at www.USAQCorp.com for more information.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” from liability for “forward-looking statements” in this press release. As an example, the Company’s statements about the market, future revenues, future products, and the potential for future results and acquisitions, are forward-looking statements. ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends’ and other similar words that express risks and uncertainties are commonly used to identify forward-looking statements. There are numerous risks and uncertainties, including, but not limited to, the timing of new product introductions and acceptance, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, and changes in government funding and budgets, as well as other factors not within the Company’s control. Any of the factors discussed herein, as well as those expressed from time to time in the Company’s SEC filings, could cause actual results or developments to differ materially from those expressed or implied by such statements. As of the date of this press release, the forward-looking statements contained herein reflect the company’s expectations only as of that date, and the company disclaims any obligation to publicly update them to reflect events or circumstances after that date.
For the Mental Health End Market, USA Equities Corp. Has Introduced the Q-Scale Product.
Expanding Product Range and Strengthening Business Model in a Large End Market
For USA’s Physician Clients, the Q-Scale represents a compelling and reimbursable value proposition.
Expanding USAQ’s Portfolio of Income Generating Products by launching new products focused on major chronic illnesses is expected.
Stay tuned for more updates with Market Research Journals.